Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival by Oberic, Lucie et al.
RESEARCH Open Access
Docetaxel- and 5-FU-concurrent radiotherapy in
patients presenting unresectable locally advanced
pancreatic cancer: a FNCLCC-ACCORD/0201
randomized phase II trial’s pre-planned analysis
and case report of a 5.5-year disease-free survival
Lucie Oberic
1, Frédéric Viret
2, Charlotte Baey
1, Marc Ychou
3, Jaafar Bennouna
4, Antoine Adenis
5, Didier Peiffert
6,
Françoise Mornex
7, Jean-Pierre Pignon
1, Patrice Celier
8, Jocelyne Berille
9 and Michel Ducreux
1,10*
Abstract
Background: To explore possible improvement in the treatment of locally advanced pancreatic carcinoma (LAPC)
we performed a randomized, non-comparative phase II study evaluating docetaxel - plus either daily continuous 5
FU or weekly cisplatin concurrent to radiotherapy. We report here the results of the docetaxel plus 5 FU regimen
stopped according to the interim analysis. The docetaxel plus cisplatin arm was continued.
Methods: Forty (40) chemotherapy-naive patients with unresectable LAPC were randomly assigned (1:1) to either
continuous fluorouracil (5-FU) 200 mg/m
2/day (protracted IV) and docetaxel (DCT) 20 mg/m
2/week or DCT 20 mg/
m
2 and cisplatin (CDDP) 20 mg/m
2, plus concurrent radiotherapy for a period of 6 weeks. The radiation dose to
the primary tumor was 54 Gy in 30 fractions. The trial’s primary endpoint was the 6-month crude non-progression
rate (NPR). Secondary endpoints were tolerance, objective response rate, and overall survival. Accrual was to be
stopped if at 6 months more than 13 disease progressions were observed in 20 patients.
Results: Eighteen (18) progressions occurred at 6 months in the 5-FU-DCT arm. Six-month NPR was 10% (95%CI:
0-23). Six and 12-month survivals were 85% (95%CI: 64-95) and 40% (95%CI: 22-61); median overall survival was 10.1
months. Median progression-free survival was 4.3 months. We report the case of one patient who was amenable
to surgery and has been in complete response (CR) for 5.5 years. Toxicities grade ≥ 3 were reported in 75% of
patients; no treatment-related death occurred. Severe toxicities were mainly vomiting (35%), abdominal pain (10%)
and fatigue (10%).
Conclusions: Combination of 5-FU, docetaxel and radiotherapy has inadequate efficacy in the treatment of LAPC
despite good tolerance for the 5-FU-DCT regimen.
Trial Registration: ClinicalTrials.gov: NCT00112697
Background
Pancreatic cancer (PC) is an extremely aggressive malig-
nancy and the 4
th cause of all cancer deaths worldwide [1].
Unfortunately, because of the typically late onset of symp-
toms and the persistent lack of early detection, the rate of
PC cases amenable to surgical resection at the time of
diagnosis has remained unchanged, around (15%-20%),
over the past decades [2]. More than 50% of patients with
PC are unresectable because of the metastatic spread of
the disease at initial presentation, and the remaining 30%
unresectable are due to local extension with vascular
involvement [3]. Overall, the acknowledged 5-year survival
rate for exocrine pancreas adenocarcinoma is around 3% -
5% [4,5]. In case of loco-regional disease development,
survival is relatively better. However, with a median
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any medium, provided the original work is properly cited.survival of only 6 to 8 months the patient’s chances of sur-
viving several years remain low. About 10%-15% of
resected patients survive more than 5 years and less than
5% more than 10 years [5,6].
Compared to radiotherapy alone, 5-FU concurrent
radiotherapy has become a widespread standard that can
be used in locally advanced PC, either pre- or post-opera-
tively [7]. In the pre-operative setting, chemoradiation is
used to gain locoregional control in the treatment of
border line resectable cancer [8]. Chemoradiation facili-
tates or makes the resection possible, especially when the
tumor is too large or if it makes contact with the vascular
system. Post-operative chemoradiation is used to
improve survival [9]. Although there is no definite evi-
dence of the superiority of either its tolerance or efficacy
compared to bolus 5-FU, continuous (protracted) 5-FU
intravenous infusion, delivered with concurrent radio-
therapy (RT), is of common use in the treatment of a
number of gastrointestinal cancers including pancreatic
and colorectal carcinoma [10,11]. Continuous infusion
insures a more constant concentration of radio-sensitiz-
ing agent at the tumor site throughout the period of
radiotherapy. Although 5-FU-based chemoradiation has
an acceptable response rate (20%) and a low toxicity,
the ideal schedule has not yet been established [12].
Docetaxel (DCT) is a semisynthetic taxane with a large
spectrum of antitumoral activity including pancreatic
cancer [13]. The activity of this drug in first-line meta-
static patients has been demonstrated as has its radiosen-
sitizing potential [14-16]. Several phase II and phase III
trials have shown that the addition of both cisplatin and
fluorouracil to docetaxel did not increase toxicity [17].
The Federation Nationale des Centres de Lutte contre
le Cancer (FNCLCC) has designed this randomized phase
II study to explore the possibility of combining DCT with
either cisplatin or 5-FU to improve concurrent chemo-
and radiation therapy in the treatment of non resectable
LAPC. We report here the study arm where docetaxel
was combined to 5-FU and briefly discuss a long-term
survival case.
Methods
Patients participating in this non-comparative, multicen-
ter, phase II study were centrally randomized at the
Gustave-Roussy Institute in Villejuif, France using mini-
mization on center, performance status and age. An
interim analysis was planned after inclusion of 20
patients in each arm. The results we report here are only
for the 5-FU-docetaxel concurrent radiotherapy arm that
was discontinued after the interim analysis. This research
was carried out in compliance with the Helsinki Declara-
tion. The protocol was approved by the Ethical Commit-
tee of Kremlin-Bicêtre, the review committees of the
FNCLCC and the participating institutions. Trial registra-
tion: Current Controlled Trials NCT00112697;
Patient Population
Patients of age > 18 years and < 75 years with pathologi-
cally confirmed unresectable locoregional advanced ade-
nocarcinoma of the exocrine pancreas were eligible.
Other histological subtype of pancreatic tumors including
neuroendocrine tumor and ampulla of Vater were not
eligible. Unresectability was defined by a surgeon and
evaluated after laparotomy or according to CT-scan and/
or endoscopic criteria, including vascular involvement.
Measurable disease was required. Patients with clinical or
radiologic diagnosis of metastases were excluded. No
prior chemotherapy was allowed; patients were required
to have a Karnofsky performance status (PS) higher than
70, adequate baseline bone marrow function (i.e., neutro-
philes count > 1,500/μL and platelets > 100,000/μL), nor-
mal serum creatinine levels (< 120 μmol/l), and bilirubin
levels < 1.5 times the upper limit of normal (ULN) after
biliary drainage. Patients with prior history of another
primary tumor within the last 10 years, except adequately
treated in situ carcinoma of the cervix uteri and basal or
squamous cell skin carcinomas, and patients with grade
II peripheral neuropathy according to NCI-CTC criteria
were excluded. Written informed consent was obtained
according to the French regulations.
Treatment Plan
Patients were randomly assigned to receive continuous
5-FU 200 mg/m
2/day and docetaxel (DCT) 20 mg/m
2/
week (Figure 1) or weekly docetaxel and cisplatin. Treat-
ment was administered for at least six weeks unless dis-
ease progression was documented, unacceptable toxicity,
or patient refusal occurred. Premedication included ade-
quate antiemetic therapy, dexamethasone (IV) before
each docetaxel infusion and prophylactic granulocyte
colony-stimulating factor (C-GSF) treatment in case of
severe hematotoxicity.
Dose adjustments were based on the worst toxicity
observed during the previous cycle. Radiotherapy con-
sisted of an initial 54 Gy in 30 fractions (dose specified
at the isocenter) with minimum photon energy of 6
MeV. The initial field covered the gross tumor volume
and regional nodes, including the celiac axis.
Response and Toxicity Evaluation
Because evaluating tumor response in LAPC is difficult,
we used progression instead of objective response as the
main study endpoint. Progressive disease (PD) was
defined as the appearance of a metastasis or protein-rich
ascites or duodenal stenosis, and/or an increase > 30% of
the lesion size calculated as the sum of the two longest
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uated with the modified RECIST scale at week 12 (i.e. 5
weeks after the treatment’s end) and every 2 months
thereafter until disease progression or patient’sd e a t h .
Toxicities were graded according to the NCICTC scale
(version 2.0) for chemotherapy, and according to the
RTOG criteria for radiotherapy.
Statistical Design
The primary endpoint was the 6-month crude non-pro-
gression rate (NPR). All eligible patients who initiated
study treatment were included in the primary endpoint
analysis. Considering a 35% control rate, the trial power
to detect a 6-month crude NPR of 60% was 93% with a
type I error of 4% based on a Fleming design [18]. An
interim analysis was planned after the first 20 enrolled
patients experienced the treatment protocol for 6
months. Enrollment was to be continued with 20 addi-
tional patients if between 8 and 12 cases of non-progres-
sion were observed at 6 months. With 7 patients or less,
the regimen would be considered non efficient and the
corresponding arm terminated. Conversely with more
than 13 out of 20 patients exhibiting non progressive
diseases, the experimental arm would therefore be
considered as active and stopped. Secondary endpoints
included adverse events, progression-free survival (PFS),
overall survival (OS), and objective response (OR)
according to the RECIST criteria. Adverse events were
evaluated before each cycle of treatment. Overall and
progression-free survivals were estimated using the
Kaplan-Meier method. Overall survival was defined as
the time from randomization to the date of death or to
the date of lost follow-up and progression-free survival as
the time from randomization to disease progression or
death, whatever its cause, or last follow-up.
Written informed consent was obtained from the
patient for publication of this case report and accompa-
nying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.’
Results
Results are reported only for arm A which was closed
prematurely, i.e. continuous infusion of 5-FU plus doce-
taxel and radiotherapy.
Patient characteristics
Between November 2003, and August 2005, 20 patients
were included in 6 centers. Patient characteristics are
Docetaxel  IV
20 mg/m²/week
5FU IV
200 mg/m²/day
Radiotherapy
1.8 Gy/day
Day 36 29 22 15 8 1
Figure 1 Treatment schedule: 5-FU + docetaxel + radiotherapy.
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patients had PS between 80 and 100. The primary
tumor location was mainly the head of the pancreas, in
70% of the enrolled patients. One patient presented
lesions in both pancreas head and body. T3 and T4
tumors represented the majority of cases, 40% and 35%
respectively.
Treatment Duration and Dose-Intensity
All 20 patients received chemotherapy and radiotherapy
(CTRT).
Chemotherapy
Median treatment duration was 6 cycles (range: [3 - 7]).
Two patients received more than 130 mg/m
2 of DCT or
8750 mg/m
2 o f5 - F U :o n eb e c a u s eh er e c e i v e do n e1 . 8
Gy fraction of radiotherapy on week 7, the other one
because of weight gain during treatment. Two patients
received less than 120 mg/m
2: one because of non
hematologic toxicity (hyperglycemia during cycle 4,
grade 4 vomiting and low blood pressure at cycle 6) and
one received a decreased dose of DCT (106 mg/m
2)f o r
6 weeks. The median relative dose-intensity was 99% of
the theoretical dose (83%-106%) for DCT, and 98%
(12%-106%) for 5-FU. Overall no treatment was stopped.
Radiotherapy
The median number of treatment sessions was 30 [26 -
31]. Fifteen patients (75%) received the planned dose of
r a d i o t h e r a p y ,i . e .5 4G yi n3 0f r a c t i o n s .O n l yo n ed e v i a -
tion was observed with respect to the protocol with a
case of non-toxicity-related prolongation of treatment
where the patient received 31 fractions of 1.8 Gy, i.e. 55.8
Gy in total. Four patients (20%) received less than 54 Gy.
Three patients received 28 fractions in 7 weeks, i.e. 50.4
Gy. Causes of treatment delay were mainly maintenance
of radiotherapy machines and bank holidays. One patient
suffered also from a pelvis fracture at week 4 and another
experienced an unspecified toxicity at week 7. One
patient received only 26 fractions in 6 weeks, i.e. 46.8 Gy.
At week 6, he received only one instead of 5 fractions
because of grade 4 vomiting and hypotension; 5-FU che-
motherapy and radiotherapy were subsequently inter-
rupted. Overall, the median number of administered
cycles was 6; there were no interruptions of treatment,
and the dose intensity was 98% of the theoretical dose.
Median dose of radiotherapy was 54 Gy; only 3 patients
received less than the theoretical dose.
Toxicity
All patients were evaluated for adverse events (Table 2).
Twelve patients (60%) experienced grade 3-4 toxicities
during CTRT treatment. There were no treatment-related
deaths. The most relevant severe toxicity involved the gas-
trointestinal tract in 17 patients (85%) including vomiting
(35%), nausea (20%), abdominal pain (10%), anorexia (5%),
diarrhea (5%), stomatitis (5%) and dyspepsia (5%). Grade 3
fatigue was observed in two patients. Grade 4 low blood
pressure (1 pt) and gastrointestinal bleeding (1 pt) related
to tumor progression occurred in two distinct patients.
Five patients experienced grade 2 weight loss. At week 12
(i.e., 5 weeks after radiochemotherapy treatment comple-
tion), toxicities of any grades affected 16 patients (80%)
and ranged from general (10 pts), hematologic (10 pts)
and gastrointestinal (9 pts) for those with highest occur-
rence rates to hepatic (4 pts), cardiovascular (1 pt) and
Table 1 Patient and tumor characteristics
Patients %
Sex
Female 9 45%
Male 11 55%
Age
≤ 60 years 9 45%
> 60 year 11 55%
Median [min - max] 62 [44 - 74] -
Performance status
80% 7 35%
90% 7 35%
100% 6 30%
Diagnostic method
Histologic 7 35%
Cytologic 13 65%
Tumor differentiation
Well 7 35%
Moderately 1 5%
Poorly or not 6 30%
Missing 6 30%
TNM classification*
T2N0 1 5%
T3N0 4 20%
T3N1 4 20%
T4N0 3 15%
T4N1 4 20%
Missing** 4 20%
Localization
Head and body 1 5%
Head alone 14 70%
Body alone 4 20%
Tail alone 1 5%
Size of lesions (mm)***
Primitive 39 [10 - 79]
Primitive + lymph nodes 42 [10 - 79]
Total 20 100%
*All tumors were M0.
** Missing: 1 T3Nx (1), T4Nx (2) and TxNx (1).
*** Median size and range for the longest tumoral diameter, data missing for
one patient.
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Page 4 of 7dermal (1 pt) for the less frequent ones. Most of them
were grades 1 or 2. However, the following toxicities
sorted by increasing severity are to be noted: grade 2 alo-
pecia and cutaneous reaction of the hands and feet (1 pt);
grade 3 hepatic toxicity (bilirubin 1 pt, GGT 1 pt) and
grade 4 pulmonary emboli and cardiac complication (1 pt).
Response and Survival
All 20 patients were assessable for response and survival.
At 6 months, 18 patients (90%) had progressive disease.
One year after week 12, the median duration of disease
stabilization was 139 days (range: 125 - 378). The best
response observed was complete response (CR) (1 pt, con-
firmed by surgery), partial response (PR) (1 pt, confirmed
by a second evaluation) and disease stabilization (DS) (10
pts) with an objective response (2 confirmed responses)
rate of 10% (95% CI, [0-23%]). The disease control rate,
partial responses (2 pts) or stable disease (10 pts), mea-
sured at week 12 was 60% (95%CI, [38-81%]). No progres-
sion was observed during treatment. Nineteen patients
(95%) died afterwards, all from their cancer within 17
months. Median overall survival time was 10 months
(range: [3 - 69] months) (Figure 2). Six- and 12-month
survival rate were 85% (95%CI, [64%-95%]) and 40% (95%
CI [22%-61%]) respectively. Median progression-free survi-
val (PFS) was 4 months (range: [2 - 69] months) (Figure 2).
PFS percentages at 3 and 6 months were 70% (95% CI,
[48% - 85%]) and 15% (95% CI, [5% - 36%]), respectively.
One patient is still alive and has been in complete remis-
sion since he underwent tumor resection 66 months ago.
Decision to stop inclusions in this study arm was subse-
quently made, due to the lack of treatment efficacy.
Long-term survival with complete remission
We observed a long-term survival showing complete
response with an absence of progression and no
detectable disease for a period of 66 months following
tumor resection. The patient, aged 55 years, was
included in the treatment protocol less than a month
after he was diagnosed as having pancreatic cancer.
Ultrasound examination revealed a tumoral lesion of
TNM grade US T3N0Mx located in the pancreas body
with no peripheral adenopathy detected. Two biopsies
w e r et a k e ns h o w i n gt h ep r e s e n c eo fa ne x o c r i n ep a n -
creatic adenocarcinoma, and no criterion indicating the
possibility of tumor surgical resection was observed.
The patient received 6 cycles of chemoradiotherapy in
compliance with the trial’s protocol. One month after the
end of chemoradiotherapy, his tumor exhibited a partial
response with a volume shrinking to 64% as well as a drop
in CA 19-9 marker count from 3000 to 30. In regard to this
remarkable result subsequent resective surgery was
proposed.
Left splenopancreatectomy was performed with tumor
margin-free en bloc resection of the pancreas body and tail
and cholecystectomy for gallstones. The en-bloc resected
piece was 10 cm long for 5 cm in diameter at the level of
the resection margin. The result of the extemporaneous
resection margin examination was suspect (presence of
non-neoplasic dystrophic lesions) and two additional trans-
verse cuts were necessary to obtain a free resected margin.
The eleven lymph nodes found were all negative (11N-/11).
One year after surgery the patient had recovered from a
weight loss of 15 kg. Sixty six (66) months after surgical
resection of his tumor, the patient was still living and in
good health (complete remission). The thorax-abdomen-
pelvis CT-scans that are performed every 6 months did not
reveal any specific sign of disease locoregional relapse or
distant extension and the CA 19-9 markers remained per-
manently low.
Discussion
In the face of the lack of progress observed during the
past two decades in the curative-intent treatment of
Table 2 Description of toxicities during CTRT
Type of toxicity Grade 3
N (%)
Grade 4
N (%)
Vomiting 5 (25%) 2 (10%)
Fatigue 2 (10%) -
Hypokalemia 2 (10%) -
Anorexia 1 (5%) -
Diarrhea 1 (5%) -
Nausea 4 (20%) -
Stomatitis 1 (5%) -
Abdominal pain 1 (5%) 1 (5%)
Dyspepsia 1 (5%) -
Hyperglycemia 1 (5%) -
Deterioration of general condition 1 (5%) -
Hypotension - 1 (5%)
Gastrointestinal bleeding - 1 (5%)
100%
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Figure 2 Overall and progression-free survival.
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current radiation therapy and chemotherapy remains the
commonly accepted treatment and the sole prospect for
improving disease outcome. However, the chemora-
diotherapy optimal schedule and whether it should be
administrated pre-operatively or post-operatively are yet
to be determined.
One essential reason to investigate neoadjuvant che-
moradiotherapy schedules relates to the possibility of
gaining disease locoregional control in unresectable or
borderline pancreatic cancer which represents a first step
toward curative intent. In a recent review, the results of
13 phase II studies, published from year 2000 onwards,
including 510 patients with unresectable LAPC treated
by standard radiotherapy and concurrent chemotherapy
were compiled [19]. This study has shown that resection
r a t e sr a n g e df r o m8t o6 4 %a n da m o n gt h eo p e r a t e d
patients, 57 to 100% (median, 87.5%) had tumor resection
with negative margin (R0). Surprisingly, in patients with
unresectable tumor at presentation, median survival after
surgery ranged from 16.4 to 32.3 months as compared
with 9 to 13 months for concurrent chemoradiation with-
out surgery. Thus, pre-operative chemoradiation can play
a beneficial role beyond palliative treatment of this type
of tumor and the design of optimally successful schedules
remains a relevant issue.
In our trial, 18 patients (90%) had progressive disease at
the time of the intermediate analysis, with a median PFS
of only 4.8 months, and a median survival of 10.1 months.
These results are not better than those achieved with
other treatment regimens for LAPC, including phase II
trials that combined radiotherapy and chemotherapy
[20-22]. In compliance with the pre-established continua-
tion/discontinuation rules of the trial, this protocol treat-
ment (docetaxel + 5-FU + RT) was not deemed efficient
enough to justify further investigations and advance to
phase III trial.
Pronounced toxicity side effects were observed during
treatment (12 pts) and in week 12 (7 pts) with a majority
of patients (75%) who have experienced grade 3-4 events,
occurring predominantly in the gastrointestinal tract.
Hematological toxicity was mild and non-hematological
symptoms were similar to those previously reported
including significant fatigue, lack of appetite, abdominal
pain, nausea and emesis [23,24]. Overall, tolerance was
comparable with other chemoradiotherapy regimens and
would not have hampered the treatment feasibility if it
had had the expected efficacy.
The concept that primarily unresectable pancreatic can-
cer are amenable to surgery is further supported by a
number of published case reports, of dramatically
advanced and/or metastatic primarily unresectable pan-
creatic cancer leading to surgical resection and ‘long-term’
survival [25-27]. In those reported cases long-term survival
usually means survival prolonged for 1-3 years which
already represents a substantial victory, especially in
regards to the minimal expectations of the initial prog-
nosis. For patients undergoing curative resection, the
prognosis appears to be determined by tumor biology
rather than factors involved in the resection [6,28,29]. The
accurate proportion of complete remission, i.e. complete
and permanent response without detectable signs of dis-
ease relapse, is to our knowledge currently not available,
but seems to be extremely low (ca. 0.2% at 3 years) in his-
tologically confirmed pancreatic carcinoma cases [30].
Further surgical and/or chemotherapeutic treatment of
metastases or second cancer is very frequent (> 50%) in 5-
year and longer survival cases also characterized by high
comorbidity [4]. Long-term complete remissions such as
the one we report here should be given more scientific
attention and systematically collected for further re-exami-
nation to help establish better prognostic and/or treatment
schedules, as they prove that there is hope even in this
most dreadful pathology [31].
Conclusions
Despite good tolerance, concurrent 5-FU-docetaxel
radiotherapy cannot be recommended as a standard of
care or even be tested in a subsequent phase III study.
Inclusions have continued in the 5-FU-cisplatin arm,
final results are awaited.
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